Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) EBITDA Margin (2021 - 2025)

Krystal Biotech (KRYS) has disclosed EBITDA Margin for 4 consecutive years, with 48.04% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 1.0% to 48.04% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 52.99% through Dec 2025, up 2258.0% year-over-year, with the annual reading at 52.98% for FY2025, 2258.0% up from the prior year.
  • EBITDA Margin hit 48.04% in Q4 2025 for Krystal Biotech, down from 81.09% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 1059.99% in Q1 2021 to a low of 0.01% in Q1 2024.
  • Historically, EBITDA Margin has averaged 212.8% across 4 years, with a median of 41.18% in 2025.
  • Biggest five-year swings in EBITDA Margin: plummeted -90705bps in 2024 and later skyrocketed 4610bps in 2025.
  • Year by year, EBITDA Margin stood at 1059.99% in 2021, then plummeted by -98bps to 23.04% in 2023, then skyrocketed by 108bps to 48.05% in 2024, then fell by 0bps to 48.04% in 2025.
  • Business Quant data shows EBITDA Margin for KRYS at 48.04% in Q4 2025, 81.09% in Q3 2025, and 40.73% in Q2 2025.